BioCentury | Dec 5, 2017
Financial News

Heron raises $150M in follow-on

...the company's Cinvanti (HTX-019) to prevent CINV. Cinvanti is a polysorbate 80-free IV formulation of aprepitant...
...with the anti-inflammatory meloxicam formulated using Biochronomer. Heron lost $1.65 (10%) to $15.50 on Tuesday. Mary Romeo APF530 aprepitant Cinvanti granisetron...
BioCentury | Nov 6, 2017
Distillery Therapeutics

Neurology

...CRLR and NK1R inhibitors. Merck & Co. Inc. and Ono Pharmaceutical Co. Ltd. market Emend aprepitant...
BioCentury | Jul 13, 2017
Targets & Mechanisms

Insider signaling

...Oral Risks Allergic reactions, diarrhea and other side effects associated with the marketed TACR1 inhibitors Emend...
...TACR1 inhibitors are marketed for chemotherapy-induced nausea and vomiting (CINV): Merck & Co. Inc. ’s Emend...
BioCentury | May 9, 2017
Distillery Therapeutics

Cancer

...& Co. Inc. and Ono Pharmaceutical Co. Ltd. market oral and IV formulations of Emend aprepitant...
BioCentury | Jan 19, 2017
Financial News

Heron raises $150M in follow-on

...Cinvanti ( HTX-019 ), another candidate for CINV. It is a polysorbate 80-free formulation of aprepitant...
BioCentury | Jan 12, 2017
Clinical News

Cinvanti regulatory update

...The company expects a decision in late 2017. Cinvanti is a polysorbate 80-free formulation of aprepitant...
BioCentury | Apr 4, 2016
Clinical News

Emend regulatory update

...Japan approved a regulatory application from Ono for IV Proemend fosaprepitant meglumine to include treatment of...
...from antineoplastic agents. Ono markets an oral formulation of the drug in Japan as Emend aprepitant...
...Osaka, Japan Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: Emend ( Ivemend - EU, Proemend...
BioCentury | Jan 11, 2016
Finance

Sowing season

...trials; submit NDA 1Q16 and 2Q16; 4Q16 Heron Therapeutics Inc. (NASDAQ:HRTX) Polysorbate 80-free formulation of aprepitant...
BioCentury | Nov 2, 2015
Clinical News

Emend regulatory update

...EMA’s CHMP recommended approval of a label expansion for Emend from Merck to include patients ages...
...NYSE:MRK), Kenilworth, N.J. Product: Emend ( Proemend ) aprepitant ( MK-0869 , MK-869 ) (formerly ONO-7436...
BioCentury | Sep 14, 2015
Clinical News

Emend aprepitant regulatory update

...FDA approved an sNDA from Merck for Emend aprepitant to prevent chemotherapy-induced nausea and vomiting (CINV...
...nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Emend...
...& Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: Emend aprepitant ( MK-0869 , MK-869 ) (formerly ONO-7436...
Items per page:
1 - 10 of 61